(R)-(1-methyl-pyrrolidin-2-yl)-acetic acid methyl ester | 140224-76-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-(1-methyl-pyrrolidin-2-yl)-acetic acid methyl ester
• 英文别名: methyl 2-[(2R)-1-methylpyrrolidin-2-yl]acetate
• CAS: 140224-76-6
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: PVKLAMRUYSTLJU-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-(1-methyl-pyrrolidin-2-yl)-acetic acid methyl ester 在 lithium aluminium deuteride 、 重水 作用下， 以 四氢呋喃 为溶剂， 以84%的产率得到(R)-2-(1-methylpyrrolidin-2-yl)ethanol-1,1-d2
  参考文献：
  名称：

  SUBSTITUTED BENZHYDRYLETHERS

  摘要：

  本文揭示了式I的取代苯基乙醚，其制备方法，药物组合物以及它们的使用方法。

  公开号：

  US20090203763A1
• 作为产物：
  描述：

  甲醇 、 (R)-2-(1-methylpyrrolidin-2-yl)acetic acid hydrochloride 在 氯化亚砜 、 sodium carbonate 作用下， 以 水 为溶剂， 以52%的产率得到(R)-(1-methyl-pyrrolidin-2-yl)-acetic acid methyl ester
  参考文献：
  名称：

  SUBSTITUTED BENZHYDRYLETHERS

  摘要：

  本文揭示了式I的取代苯基乙醚，其制备方法，药物组合物以及它们的使用方法。

  公开号：

  US20090203763A1

文献信息

• Triazolo-pyrimidine compounds and uses thereof
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US10858365B2

  公开（公告）日：2020-12-08

  The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

  本公开涉及靶向腺苷受体（尤其是A1和A2，特别是A2a）的新型三唑并嘧啶化合物。本公开还涉及包含一种或多种化合物作为活性成分的药物组合物，以及这些化合物在治疗腺苷受体（AR）相关疾病中的用途，例如癌症，如NSCLC、RCC、前列腺癌和乳腺癌。
• TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US20200331918A1

  公开（公告）日：2020-10-22

  The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
• [EN] SUBSTITUTED BENZHYDRYLETHERS<br/>[FR] BENZHYDRYLÉTHERS SUBSTITUÉS
  申请人：AUSPEX PHARMACEUTICALS

  公开号：WO2009094457A2

  公开（公告）日：2009-07-30

  Disclosed herein are substituted benzhydrylethers of Formula (I), processes of preparation thereof, pharmaceutical compositions thereof, and methods of their use therof.
• [EN] TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLO-PYRIMIDINE ET LEURS UTILISATIONS
  申请人：DIZAL JIANGSU PHARMACEUTICAL CO LTD

  公开号：WO2020052631A1

  公开（公告）日：2020-03-19

  The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
• SUBSTITUTED BENZHYDRYLETHERS
  申请人：Gant Thomas G.

  公开号：US20090203763A1

  公开（公告）日：2009-08-13

  Disclosed herein are substituted benzhydrylethers of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of their use thereof.

  本文揭示了式I的取代苯基乙醚，其制备方法，药物组合物以及它们的使用方法。